TX Q&A

To conduct a biocompatibility evaluation for a single-use abdominal puncture device, follow the evaluation requirements specified in the GB/T 16886 series of standards. This product is an external access device that comes into contact with human tissue for a short duration not exceeding 24 hours. The evaluation should include at least the following items: cytotoxicity, sensitization reactions, and intradermal reactions.

For conventional ultra-high molecular weight polyethylene orthopedic implant products, applicants should evaluate the stability of the material (such as oxidation index and mechanical properties before and after aging) and morphology according to the methods in standards YY/T 0772.3, YY/T 0772.4, and YY/T 0772.5. These methods do not simulate the relationship between test conditions and real-time storage aging of the product, so they cannot be considered equivalent to product stability studies. In the accelerated aging tests of product stability studies, the test conditions assume that the chemical reactions involved in material degradation follow the Arrhenius function, allowing for the inference of material aging under normal storage conditions. Therefore, the stability of the product (including shelf life) should be studied following the "Guiding Principles for Stability Studies of Passive Implantable Medical Devices," and real-time stability or accelerated stability study data should be submitted.

In the "Items Needed but Not Provided" section of the in vitro diagnostic reagents instructions, you should list the names of reagents required for testing but not included in the test kit. If the reagent has obtained a registration number/filing number, you should indicate "Registration Number/Filing Number and Product Number." If the reagent is currently in the registration/filing stage, you should indicate "Product Number and Registration Number: (blank)/Filing Number: (blank)," and the specific document numbers should be added by the registrant after the completion of registration/filing.

Clinical infusion and high-pressure contrast agent injection are two different applications. It is recommended to differentiate and declare them under separate registration units.

Recommendation: Simulate clinical usage. Ensure that the endoscopic injection needle can smoothly enter and exit the endoscope (or an endoscope simulator channel, with design information provided to prove its clinical suitability). Check for free movement without significant resistance, jamming, or twisting. Evaluate the flexibility and functionality of all components to meet usage requirements. Study aspects such as smooth and normal insertion and retraction of the needle multiple times, with no breakage or detachment at connection points.

According to the "Classification Catalog," blood dialysis concentrate usually consists of components A and B, with component A typically being acetate or an acidic mixture. Packaging component A separately based on its components would increase the operational steps in clinical use and the risk of not mixing in the expected proportions. Therefore, component A should not be separately packaged based on its components.

In principle, the thickness of the load-bearing area of conventional ultra-high molecular weight polyethylene liners used in unicompartmental knee joint prostheses in conjunction with tibial component should be at least 6mm. If the product design cannot meet this thickness requirement, the manufacturer should provide design justifications and reasonable explanations, demonstrating that the design can ensure the clinical safety and effectiveness of the product, along with providing corresponding supportive evidence. In comparison with similar products already on the market, the submission should include a comprehensive evaluation based on structural design, key dimensions, mechanical performance, and clinical application of the existing products. This evaluation can be supported by referencing clinical literature data, adverse event data, and other relevant evidence related to similar products on the market.

For rapid exchange (Rx) balloon dilatation catheter products, the catheter hub does not come into contact with the human body and therefore does not require biological evaluation. For coaxial over-the-wire (OTW) balloon dilatation catheters, other pathway catheter products, etc., the catheter hub generally comes into indirect contact with blood. The biological evaluation of such products should include the catheter hub that comes into indirect contact with blood. During biological testing, samples should include the inner and outer surfaces of the catheter hub.

HCV belongs to the Flaviviridae family, with a genome consisting of single-stranded positive-sense RNA that is prone to mutation. Currently, it is classified into 6 genotypes, with genotypes HCV1b and 2a being the most common in China; genotype 6 is mainly found in the southern regions. In related product clinical trials, it is important to include positive samples from different genotypes as much as possible (specific numbers can refer to the requirements of hepatitis C guidelines), and should cover the main genotypes prevalent domestically. For the rare genotypes 4 and 5 in China, if their inclusivity has been sufficiently validated in preclinical studies, it is not required to evaluate these genotypes with serum panels or other sample types in clinical trials. The limitations of the testing method should be noted in the instructions for use, stating that due to limited sample volume, there is no sufficient clinical evaluation data to support the detection performance of the product for genotypes 4 and 5.

Referencing the current GB/T 16886 series standards, the overall biological evaluation should consider the following aspects: (1) Materials used in manufacturing; (2) Expected additives, process contaminants, and residues; (3) Leachable substances; (4) Degradation products (if applicable); (5) Other components and their interactions in the final product; (6) Performance and characteristics of the final product; (7) Physical properties of the final product, including but not limited to porosity, particle size, physical state, and surface morphology. Based on the clinical intended use of blood purification products, the biological evaluation should consider the cumulative effect time, following the requirements for external devices in prolonged contact with circulating blood. If the product uses new materials, or may contain carcinogenic, mutagenic, and/or reproductive toxic substances, it is also recommended to consider related endpoints in the risk assessment.